How the EPO’s latest CRISPR revocation affects the Cas9 landscape
Sigma-Aldrich’s patent loss could be a sign of things to come for several ongoing opposition proceedings
To read more
Register for limited access
Register to receive our newsletter and gain limited access to subscriber content.
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the IAM experts.